CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Carisma Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Carisma Therapeutics Inc
245 1st St Ste 1800
Phone: (617) 444-8550p:617 444-8550 CAMBRIDGE, MA  02142-1292  United States Ticker: CARMCARM

On 3/7/2023, Sesen Bio, Inc. completed a merger with Carisma Therapeutics to form Carisma Therapeutics Inc.

Business Summary
Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company’s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company’s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company’s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board SanfordZweifach 67 3/7/2023 3/7/2023
President, Chief Executive Officer, Director StevenKelly 58 3/7/2023 3/7/2023
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Chief Complianc Richard S.Morris 49 3/7/2023 3/7/2023
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Viventia Bio Inc 147 Hamelin St WINNIPEG MB Canada

Business Names
Business Name
CARM
EBIO
Seahawk Merger Sub, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 17 (As of 12/31/2022)
Outstanding Shares: 40,356,806 (As of 11/6/2023)
Shareholders: 17
Stock Exchange: NASD
Federal Tax Id: 262025616
Fax Number: (617) 858-0911
Email Address: info@elevenbio.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024